Established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs, Pathios Therapeutics is based in Oxford, UK, and is focused on identifying novel small-molecule modulators of GPR65 with expected utility across a broad spectrum of cancers and other serious diseases. The company combines experienced scientific leaders with strategic external partnerships to efficiently carry out drug discovery and scientific activities, capitalizing on the latest advances in GPCR drug discovery.